Neurologix, Inc. is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, primarily utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy. The Company's core technology, which it refers to as "NLX," is in the clinical development stages, having recently been tested in a Phase I human clinical trial to treat Parkinson's disease.
After a number of price hesitations, Neurologix, Inc. (OTC:NRGX) crashed down hard. Yesterday, the stock lost 35.23% on the market, while its traded volume jumped over 448 thousand shares.read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
After a number of price hesitations, Neurologix, Inc. (OTC:NRGX) crashed down hard. Yesterday, the stock lost 35.23% on the market, while its traded volume jumped over 448 thousand shares.read more
